Abstract
Adaptation and resistance to treatment are the results of a multitude of (epi)genetic events unmasked or directly triggered by therapies targeting the genetic driver(s) of a dominant cell population within a tumor mass. Rusan and colleagues report that drug-tolerant cells are sensitive to THZ1, a dual CDK7/12 inhibitor, which, by impairing the transcriptional machinery, can prevent cellular rewiring to survive therapeutic attack.
Original language | English (US) |
---|---|
Pages (from-to) | 17-19 |
Number of pages | 3 |
Journal | Cancer discovery |
Volume | 8 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2018 |
ASJC Scopus subject areas
- Oncology